SAN DIEGO (AP) — A company that claims to have the first drug to slow mental decline from Alzheimer’s disease made its case to scientists Thursday, disclosing more results that may help explain why one study of the experimental medicine succeeded and another failed. Excitement and skepticism have surrounded aducanumab since its developers stopped studies […]
This story is from The Seattle Times. Read the rest of this News story at https://www.seattletimes.com/business/new-details-emerge-on-drug-that-may-slow-alzheimers-disease/?utm_source=RSS&utm_medium=Referral&utm_campaign=RSS_seattle-news.
Get real time update about this post categories directly on your device, subscribe now.